nodes	percent_of_prediction	percent_of_DWPC	metapath
Carmustine—Alkylating Activity—Mitomycin—urinary bladder cancer	0.487	0.569	CiPCiCtD
Carmustine—Alkylating Activity—Thiotepa—urinary bladder cancer	0.369	0.431	CiPCiCtD
Carmustine—GSR—Synthesis and interconversion of nucleotide di- and triphosphates—RRM2—urinary bladder cancer	0.00274	0.0726	CbGpPWpGaD
Carmustine—GSR—prostate gland—urinary bladder cancer	0.00218	0.174	CbGeAlD
Carmustine—CYP1A2—urine—urinary bladder cancer	0.00206	0.165	CbGeAlD
Carmustine—GSR—seminal vesicle—urinary bladder cancer	0.00184	0.148	CbGeAlD
Carmustine—GSR—renal system—urinary bladder cancer	0.00148	0.119	CbGeAlD
Carmustine—GSR—urethra—urinary bladder cancer	0.00146	0.117	CbGeAlD
Carmustine—GSR—Oxidative Stress—NQO1—urinary bladder cancer	0.00136	0.036	CbGpPWpGaD
Carmustine—GSR—Glutathione metabolism—GSTM1—urinary bladder cancer	0.00129	0.0341	CbGpPWpGaD
Carmustine—GSR—Glutathione metabolism—GPX1—urinary bladder cancer	0.00123	0.0327	CbGpPWpGaD
Carmustine—GSR—Detoxification of Reactive Oxygen Species—GSTP1—urinary bladder cancer	0.00123	0.0327	CbGpPWpGaD
Carmustine—GSR—female reproductive system—urinary bladder cancer	0.00119	0.0952	CbGeAlD
Carmustine—GSR—Detoxification of Reactive Oxygen Species—SOD2—urinary bladder cancer	0.00114	0.0301	CbGpPWpGaD
Carmustine—GSR—Nucleotide metabolism—TYMP—urinary bladder cancer	0.00109	0.0288	CbGpPWpGaD
Carmustine—GSR—Detoxification of Reactive Oxygen Species—GPX1—urinary bladder cancer	0.00108	0.0288	CbGpPWpGaD
Carmustine—GSR—vagina—urinary bladder cancer	0.00107	0.0861	CbGeAlD
Carmustine—GSR—Oxidative Stress—SOD2—urinary bladder cancer	0.00105	0.0277	CbGpPWpGaD
Carmustine—GSR—Oxidative Stress—GPX1—urinary bladder cancer	0.000997	0.0264	CbGpPWpGaD
Carmustine—GSR—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000992	0.0263	CbGpPWpGaD
Carmustine—GSR—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00099	0.0262	CbGpPWpGaD
Carmustine—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00094	0.0249	CbGpPWpGaD
Carmustine—GSR—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000939	0.0249	CbGpPWpGaD
Carmustine—GSR—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000858	0.0228	CbGpPWpGaD
Carmustine—GSR—Nucleotide metabolism—RRM2—urinary bladder cancer	0.000847	0.0225	CbGpPWpGaD
Carmustine—GSR—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000773	0.0205	CbGpPWpGaD
Carmustine—GSR—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000704	0.0187	CbGpPWpGaD
Carmustine—GSR—lymph node—urinary bladder cancer	0.000695	0.0557	CbGeAlD
Carmustine—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.000652	0.0173	CbGpPWpGaD
Carmustine—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000576	0.0153	CbGpPWpGaD
Carmustine—GSR—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000514	0.0136	CbGpPWpGaD
Carmustine—CYP1A2—renal system—urinary bladder cancer	0.000504	0.0404	CbGeAlD
Carmustine—GSR—Nucleotide metabolism—TYMS—urinary bladder cancer	0.000491	0.013	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—VHL—urinary bladder cancer	0.000488	0.0129	CbGpPWpGaD
Carmustine—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000467	0.0124	CbGpPWpGaD
Carmustine—GSR—Nucleotide metabolism—GPX1—urinary bladder cancer	0.000464	0.0123	CbGpPWpGaD
Carmustine—GSR—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000442	0.0117	CbGpPWpGaD
Carmustine—GSR—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000422	0.0112	CbGpPWpGaD
Carmustine—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000411	0.0109	CbGpPWpGaD
Carmustine—GSR—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000389	0.0103	CbGpPWpGaD
Carmustine—GSR—NRF2 pathway—NQO1—urinary bladder cancer	0.000383	0.0102	CbGpPWpGaD
Carmustine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000353	0.00935	CbGpPWpGaD
Carmustine—GSR—NRF2 pathway—GSTP1—urinary bladder cancer	0.00032	0.00847	CbGpPWpGaD
Carmustine—GSR—NRF2 pathway—GSTM1—urinary bladder cancer	0.000294	0.00778	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—RBX1—urinary bladder cancer	0.000281	0.00743	CbGpPWpGaD
Carmustine—GSR—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000276	0.00733	CbGpPWpGaD
Carmustine—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000259	0.00687	CbGpPWpGaD
Carmustine—GSR—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000254	0.00673	CbGpPWpGaD
Carmustine—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.000252	0.00667	CbGpPWpGaD
Carmustine—GSR—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000248	0.00658	CbGpPWpGaD
Carmustine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000224	0.00594	CbGpPWpGaD
Carmustine—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000221	0.00586	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.000211	0.0056	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.0002	0.00531	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.0002	0.00531	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—GSTP1—urinary bladder cancer	0.000199	0.00527	CbGpPWpGaD
Carmustine—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000197	0.00521	CbGpPWpGaD
Carmustine—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000193	0.00511	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—CCNE1—urinary bladder cancer	0.000188	0.00499	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—SOD2—urinary bladder cancer	0.000184	0.00486	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000183	0.00485	CbGpPWpGaD
Carmustine—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000182	0.00481	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—GPX1—urinary bladder cancer	0.000175	0.00464	CbGpPWpGaD
Carmustine—GSR—Metabolism—GSTZ1—urinary bladder cancer	0.000172	0.00455	CbGpPWpGaD
Carmustine—GSR—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000168	0.00444	CbGpPWpGaD
Carmustine—GSR—Metabolism—GSTO2—urinary bladder cancer	0.000163	0.00431	CbGpPWpGaD
Carmustine—GSR—Metabolism—NAT1—urinary bladder cancer	0.000163	0.00431	CbGpPWpGaD
Carmustine—GSR—Metabolism—UGT2B7—urinary bladder cancer	0.000149	0.00395	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000147	0.00391	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—ATM—urinary bladder cancer	0.000145	0.00384	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—CDK4—urinary bladder cancer	0.000144	0.00382	CbGpPWpGaD
Carmustine—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000138	0.00365	CbGpPWpGaD
Carmustine—GSR—Metabolism—CYP4B1—urinary bladder cancer	0.000134	0.00355	CbGpPWpGaD
Carmustine—GSR—Metabolism—SLC19A1—urinary bladder cancer	0.000127	0.00335	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—CREBBP—urinary bladder cancer	0.000126	0.00334	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—RB1—urinary bladder cancer	0.000125	0.00332	CbGpPWpGaD
Carmustine—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000124	0.00327	CbGpPWpGaD
Carmustine—GSR—Metabolism—PRSS3—urinary bladder cancer	0.000123	0.00327	CbGpPWpGaD
Carmustine—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000122	0.00323	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000119	0.00315	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000119	0.00315	CbGpPWpGaD
Carmustine—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000117	0.0031	CbGpPWpGaD
Carmustine—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000117	0.0031	CbGpPWpGaD
Carmustine—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000116	0.00306	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—CDKN2A—urinary bladder cancer	0.00011	0.00292	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.00011	0.00291	CbGpPWpGaD
Carmustine—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000107	0.00284	CbGpPWpGaD
Carmustine—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000106	0.0028	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—CXCL8—urinary bladder cancer	0.0001	0.00265	CbGpPWpGaD
Carmustine—GSR—Metabolism—TYMP—urinary bladder cancer	9.86e-05	0.00261	CbGpPWpGaD
Carmustine—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	9.65e-05	0.00256	CbGpPWpGaD
Carmustine—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	9.51e-05	0.00252	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—CDKN1A—urinary bladder cancer	9.01e-05	0.00239	CbGpPWpGaD
Carmustine—GSR—Metabolism—NAT2—urinary bladder cancer	8.92e-05	0.00236	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	8.77e-05	0.00232	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—EP300—urinary bladder cancer	8.57e-05	0.00227	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	8.51e-05	0.00225	CbGpPWpGaD
Carmustine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.31e-05	0.0022	CbGpPWpGaD
Carmustine—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	8.16e-05	0.00216	CbGpPWpGaD
Carmustine—GSR—Metabolism—RRM2—urinary bladder cancer	7.7e-05	0.00204	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	7.15e-05	0.0019	CbGpPWpGaD
Carmustine—GSR—Metabolism—ENO2—urinary bladder cancer	7.13e-05	0.00189	CbGpPWpGaD
Carmustine—GSR—Metabolism—HPGDS—urinary bladder cancer	7.13e-05	0.00189	CbGpPWpGaD
Carmustine—GSR—Metabolism—GSTT1—urinary bladder cancer	6.91e-05	0.00183	CbGpPWpGaD
Carmustine—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	6.42e-05	0.0017	CbGpPWpGaD
Carmustine—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	6.33e-05	0.00168	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	6.24e-05	0.00165	CbGpPWpGaD
Carmustine—GSR—Cellular responses to stress—TP53—urinary bladder cancer	6.13e-05	0.00163	CbGpPWpGaD
Carmustine—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	5.9e-05	0.00156	CbGpPWpGaD
Carmustine—GSR—Metabolism—NQO1—urinary bladder cancer	5.75e-05	0.00152	CbGpPWpGaD
Carmustine—Face oedema—Doxorubicin—urinary bladder cancer	5.58e-05	0.000594	CcSEcCtD
Carmustine—Decreased appetite—Gemcitabine—urinary bladder cancer	5.57e-05	0.000594	CcSEcCtD
Carmustine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	5.53e-05	0.00059	CcSEcCtD
Carmustine—Confusional state—Etoposide—urinary bladder cancer	5.52e-05	0.000588	CcSEcCtD
Carmustine—Muscular weakness—Epirubicin—urinary bladder cancer	5.51e-05	0.000587	CcSEcCtD
Carmustine—Constipation—Gemcitabine—urinary bladder cancer	5.48e-05	0.000584	CcSEcCtD
Carmustine—Pain—Gemcitabine—urinary bladder cancer	5.48e-05	0.000584	CcSEcCtD
Carmustine—Decreased appetite—Fluorouracil—urinary bladder cancer	5.48e-05	0.000584	CcSEcCtD
Carmustine—Pancytopenia—Methotrexate—urinary bladder cancer	5.47e-05	0.000584	CcSEcCtD
Carmustine—Asthenia—Thiotepa—urinary bladder cancer	5.47e-05	0.000583	CcSEcCtD
Carmustine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	5.44e-05	0.00058	CcSEcCtD
Carmustine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	5.44e-05	0.00058	CcSEcCtD
Carmustine—Infection—Etoposide—urinary bladder cancer	5.44e-05	0.00058	CcSEcCtD
Carmustine—Ataxia—Doxorubicin—urinary bladder cancer	5.43e-05	0.000579	CcSEcCtD
Carmustine—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	5.42e-05	0.00144	CbGpPWpGaD
Carmustine—Dysphagia—Epirubicin—urinary bladder cancer	5.39e-05	0.000575	CcSEcCtD
Carmustine—Neutropenia—Methotrexate—urinary bladder cancer	5.39e-05	0.000575	CcSEcCtD
Carmustine—Pain—Fluorouracil—urinary bladder cancer	5.39e-05	0.000574	CcSEcCtD
Carmustine—Paraesthesia—Cisplatin—urinary bladder cancer	5.36e-05	0.000572	CcSEcCtD
Carmustine—Thrombocytopenia—Etoposide—urinary bladder cancer	5.36e-05	0.000571	CcSEcCtD
Carmustine—Tachycardia—Etoposide—urinary bladder cancer	5.34e-05	0.000569	CcSEcCtD
Carmustine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	5.33e-05	0.000568	CcSEcCtD
Carmustine—Dyspnoea—Cisplatin—urinary bladder cancer	5.33e-05	0.000568	CcSEcCtD
Carmustine—Feeling abnormal—Gemcitabine—urinary bladder cancer	5.28e-05	0.000563	CcSEcCtD
Carmustine—Hypokalaemia—Doxorubicin—urinary bladder cancer	5.26e-05	0.00056	CcSEcCtD
Carmustine—Anorexia—Etoposide—urinary bladder cancer	5.22e-05	0.000556	CcSEcCtD
Carmustine—Diarrhoea—Thiotepa—urinary bladder cancer	5.21e-05	0.000556	CcSEcCtD
Carmustine—Decreased appetite—Cisplatin—urinary bladder cancer	5.19e-05	0.000554	CcSEcCtD
Carmustine—Feeling abnormal—Fluorouracil—urinary bladder cancer	5.19e-05	0.000554	CcSEcCtD
Carmustine—Pneumonia—Methotrexate—urinary bladder cancer	5.17e-05	0.000551	CcSEcCtD
Carmustine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	5.16e-05	0.00055	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	5.13e-05	0.00136	CbGpPWpGaD
Carmustine—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	5.13e-05	0.00136	CbGpPWpGaD
Carmustine—Depression—Methotrexate—urinary bladder cancer	5.13e-05	0.000546	CcSEcCtD
Carmustine—Pancytopenia—Epirubicin—urinary bladder cancer	5.12e-05	0.000546	CcSEcCtD
Carmustine—Hypotension—Etoposide—urinary bladder cancer	5.11e-05	0.000545	CcSEcCtD
Carmustine—Pain—Cisplatin—urinary bladder cancer	5.11e-05	0.000545	CcSEcCtD
Carmustine—Muscular weakness—Doxorubicin—urinary bladder cancer	5.09e-05	0.000543	CcSEcCtD
Carmustine—Body temperature increased—Gemcitabine—urinary bladder cancer	5.07e-05	0.00054	CcSEcCtD
Carmustine—Renal failure—Methotrexate—urinary bladder cancer	5.05e-05	0.000539	CcSEcCtD
Carmustine—Neutropenia—Epirubicin—urinary bladder cancer	5.04e-05	0.000538	CcSEcCtD
Carmustine—Dizziness—Thiotepa—urinary bladder cancer	5.04e-05	0.000537	CcSEcCtD
Carmustine—Stomatitis—Methotrexate—urinary bladder cancer	5.01e-05	0.000534	CcSEcCtD
Carmustine—Dysphagia—Doxorubicin—urinary bladder cancer	4.99e-05	0.000532	CcSEcCtD
Carmustine—Body temperature increased—Fluorouracil—urinary bladder cancer	4.98e-05	0.000531	CcSEcCtD
Carmustine—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	4.98e-05	0.00132	CbGpPWpGaD
Carmustine—Feeling abnormal—Cisplatin—urinary bladder cancer	4.92e-05	0.000525	CcSEcCtD
Carmustine—Paraesthesia—Etoposide—urinary bladder cancer	4.91e-05	0.000524	CcSEcCtD
Carmustine—Dyspnoea—Etoposide—urinary bladder cancer	4.88e-05	0.00052	CcSEcCtD
Carmustine—Hyperglycaemia—Epirubicin—urinary bladder cancer	4.87e-05	0.000519	CcSEcCtD
Carmustine—Somnolence—Etoposide—urinary bladder cancer	4.87e-05	0.000519	CcSEcCtD
Carmustine—Vomiting—Thiotepa—urinary bladder cancer	4.84e-05	0.000516	CcSEcCtD
Carmustine—Pneumonia—Epirubicin—urinary bladder cancer	4.84e-05	0.000516	CcSEcCtD
Carmustine—Rash—Thiotepa—urinary bladder cancer	4.8e-05	0.000512	CcSEcCtD
Carmustine—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	4.8e-05	0.00127	CbGpPWpGaD
Carmustine—Dermatitis—Thiotepa—urinary bladder cancer	4.8e-05	0.000512	CcSEcCtD
Carmustine—GSR—Metabolism—GSTP1—urinary bladder cancer	4.79e-05	0.00127	CbGpPWpGaD
Carmustine—Headache—Thiotepa—urinary bladder cancer	4.77e-05	0.000509	CcSEcCtD
Carmustine—Decreased appetite—Etoposide—urinary bladder cancer	4.76e-05	0.000507	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	4.76e-05	0.00126	CbGpPWpGaD
Carmustine—Pancytopenia—Doxorubicin—urinary bladder cancer	4.74e-05	0.000505	CcSEcCtD
Carmustine—Renal failure—Epirubicin—urinary bladder cancer	4.73e-05	0.000504	CcSEcCtD
Carmustine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	4.73e-05	0.000504	CcSEcCtD
Carmustine—Body temperature increased—Cisplatin—urinary bladder cancer	4.72e-05	0.000503	CcSEcCtD
Carmustine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	4.72e-05	0.000503	CcSEcCtD
Carmustine—Stomatitis—Epirubicin—urinary bladder cancer	4.69e-05	0.0005	CcSEcCtD
Carmustine—Constipation—Etoposide—urinary bladder cancer	4.68e-05	0.000499	CcSEcCtD
Carmustine—Pain—Etoposide—urinary bladder cancer	4.68e-05	0.000499	CcSEcCtD
Carmustine—Urinary tract infection—Epirubicin—urinary bladder cancer	4.68e-05	0.000498	CcSEcCtD
Carmustine—Neutropenia—Doxorubicin—urinary bladder cancer	4.67e-05	0.000498	CcSEcCtD
Carmustine—Hypersensitivity—Fluorouracil—urinary bladder cancer	4.64e-05	0.000495	CcSEcCtD
Carmustine—Haemoglobin—Methotrexate—urinary bladder cancer	4.64e-05	0.000494	CcSEcCtD
Carmustine—Haemorrhage—Methotrexate—urinary bladder cancer	4.61e-05	0.000492	CcSEcCtD
Carmustine—Asthenia—Gemcitabine—urinary bladder cancer	4.6e-05	0.00049	CcSEcCtD
Carmustine—Nausea—Thiotepa—urinary bladder cancer	4.53e-05	0.000482	CcSEcCtD
Carmustine—Feeling abnormal—Etoposide—urinary bladder cancer	4.51e-05	0.000481	CcSEcCtD
Carmustine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	4.5e-05	0.00048	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	4.49e-05	0.00119	CbGpPWpGaD
Carmustine—Pneumonia—Doxorubicin—urinary bladder cancer	4.48e-05	0.000477	CcSEcCtD
Carmustine—Gastrointestinal pain—Etoposide—urinary bladder cancer	4.48e-05	0.000477	CcSEcCtD
Carmustine—GSR—Metabolism—TYMS—urinary bladder cancer	4.46e-05	0.00118	CbGpPWpGaD
Carmustine—Visual impairment—Methotrexate—urinary bladder cancer	4.45e-05	0.000474	CcSEcCtD
Carmustine—GSR—Metabolism—NCOR1—urinary bladder cancer	4.4e-05	0.00117	CbGpPWpGaD
Carmustine—GSR—Metabolism—GSTM1—urinary bladder cancer	4.4e-05	0.00117	CbGpPWpGaD
Carmustine—Hypersensitivity—Cisplatin—urinary bladder cancer	4.4e-05	0.000469	CcSEcCtD
Carmustine—Diarrhoea—Gemcitabine—urinary bladder cancer	4.39e-05	0.000467	CcSEcCtD
Carmustine—Renal failure—Doxorubicin—urinary bladder cancer	4.38e-05	0.000466	CcSEcCtD
Carmustine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	4.36e-05	0.000465	CcSEcCtD
Carmustine—Haemoglobin—Epirubicin—urinary bladder cancer	4.34e-05	0.000463	CcSEcCtD
Carmustine—Stomatitis—Doxorubicin—urinary bladder cancer	4.34e-05	0.000462	CcSEcCtD
Carmustine—Body temperature increased—Etoposide—urinary bladder cancer	4.33e-05	0.000461	CcSEcCtD
Carmustine—Abdominal pain—Etoposide—urinary bladder cancer	4.33e-05	0.000461	CcSEcCtD
Carmustine—Urinary tract infection—Doxorubicin—urinary bladder cancer	4.33e-05	0.000461	CcSEcCtD
Carmustine—Haemorrhage—Epirubicin—urinary bladder cancer	4.32e-05	0.00046	CcSEcCtD
Carmustine—Eye disorder—Methotrexate—urinary bladder cancer	4.31e-05	0.00046	CcSEcCtD
Carmustine—Diarrhoea—Fluorouracil—urinary bladder cancer	4.31e-05	0.00046	CcSEcCtD
Carmustine—Hypoaesthesia—Epirubicin—urinary bladder cancer	4.3e-05	0.000458	CcSEcCtD
Carmustine—Asthenia—Cisplatin—urinary bladder cancer	4.29e-05	0.000457	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	4.27e-05	0.00113	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	4.27e-05	0.00113	CbGpPWpGaD
Carmustine—Oedema peripheral—Epirubicin—urinary bladder cancer	4.25e-05	0.000453	CcSEcCtD
Carmustine—Connective tissue disorder—Epirubicin—urinary bladder cancer	4.24e-05	0.000452	CcSEcCtD
Carmustine—GSR—Metabolism—GPX1—urinary bladder cancer	4.22e-05	0.00112	CbGpPWpGaD
Carmustine—Dizziness—Fluorouracil—urinary bladder cancer	4.17e-05	0.000444	CcSEcCtD
Carmustine—Visual impairment—Epirubicin—urinary bladder cancer	4.16e-05	0.000444	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	4.15e-05	0.0011	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	4.15e-05	0.0011	CbGpPWpGaD
Carmustine—GSR—Metabolism—ERCC2—urinary bladder cancer	4.14e-05	0.0011	CbGpPWpGaD
Carmustine—Diarrhoea—Cisplatin—urinary bladder cancer	4.09e-05	0.000436	CcSEcCtD
Carmustine—Alopecia—Methotrexate—urinary bladder cancer	4.08e-05	0.000435	CcSEcCtD
Carmustine—Vomiting—Gemcitabine—urinary bladder cancer	4.08e-05	0.000434	CcSEcCtD
Carmustine—Mental disorder—Methotrexate—urinary bladder cancer	4.04e-05	0.000431	CcSEcCtD
Carmustine—Rash—Gemcitabine—urinary bladder cancer	4.04e-05	0.000431	CcSEcCtD
Carmustine—Dermatitis—Gemcitabine—urinary bladder cancer	4.04e-05	0.00043	CcSEcCtD
Carmustine—Eye disorder—Epirubicin—urinary bladder cancer	4.04e-05	0.00043	CcSEcCtD
Carmustine—Hypersensitivity—Etoposide—urinary bladder cancer	4.03e-05	0.00043	CcSEcCtD
Carmustine—Malnutrition—Methotrexate—urinary bladder cancer	4.02e-05	0.000428	CcSEcCtD
Carmustine—Erythema—Methotrexate—urinary bladder cancer	4.02e-05	0.000428	CcSEcCtD
Carmustine—Haemoglobin—Doxorubicin—urinary bladder cancer	4.02e-05	0.000428	CcSEcCtD
Carmustine—Headache—Gemcitabine—urinary bladder cancer	4.02e-05	0.000428	CcSEcCtD
Carmustine—Flushing—Epirubicin—urinary bladder cancer	4.01e-05	0.000427	CcSEcCtD
Carmustine—Vomiting—Fluorouracil—urinary bladder cancer	4.01e-05	0.000427	CcSEcCtD
Carmustine—Haemorrhage—Doxorubicin—urinary bladder cancer	4e-05	0.000426	CcSEcCtD
Carmustine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	3.98e-05	0.000424	CcSEcCtD
Carmustine—Rash—Fluorouracil—urinary bladder cancer	3.97e-05	0.000424	CcSEcCtD
Carmustine—Dermatitis—Fluorouracil—urinary bladder cancer	3.97e-05	0.000423	CcSEcCtD
Carmustine—Headache—Fluorouracil—urinary bladder cancer	3.95e-05	0.000421	CcSEcCtD
Carmustine—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.94e-05	0.00042	CcSEcCtD
Carmustine—Asthenia—Etoposide—urinary bladder cancer	3.93e-05	0.000419	CcSEcCtD
Carmustine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	3.93e-05	0.000419	CcSEcCtD
Carmustine—GSR—Metabolism—MTHFR—urinary bladder cancer	3.89e-05	0.00103	CbGpPWpGaD
Carmustine—Back pain—Methotrexate—urinary bladder cancer	3.89e-05	0.000414	CcSEcCtD
Carmustine—Arrhythmia—Epirubicin—urinary bladder cancer	3.86e-05	0.000411	CcSEcCtD
Carmustine—Visual impairment—Doxorubicin—urinary bladder cancer	3.85e-05	0.00041	CcSEcCtD
Carmustine—Alopecia—Epirubicin—urinary bladder cancer	3.82e-05	0.000407	CcSEcCtD
Carmustine—Nausea—Gemcitabine—urinary bladder cancer	3.81e-05	0.000406	CcSEcCtD
Carmustine—Vomiting—Cisplatin—urinary bladder cancer	3.8e-05	0.000405	CcSEcCtD
Carmustine—Vision blurred—Methotrexate—urinary bladder cancer	3.79e-05	0.000404	CcSEcCtD
Carmustine—Mental disorder—Epirubicin—urinary bladder cancer	3.78e-05	0.000403	CcSEcCtD
Carmustine—Rash—Cisplatin—urinary bladder cancer	3.77e-05	0.000401	CcSEcCtD
Carmustine—Dermatitis—Cisplatin—urinary bladder cancer	3.76e-05	0.000401	CcSEcCtD
Carmustine—Malnutrition—Epirubicin—urinary bladder cancer	3.76e-05	0.000401	CcSEcCtD
Carmustine—Erythema—Epirubicin—urinary bladder cancer	3.76e-05	0.000401	CcSEcCtD
Carmustine—Diarrhoea—Etoposide—urinary bladder cancer	3.74e-05	0.000399	CcSEcCtD
Carmustine—Nausea—Fluorouracil—urinary bladder cancer	3.74e-05	0.000399	CcSEcCtD
Carmustine—Eye disorder—Doxorubicin—urinary bladder cancer	3.73e-05	0.000398	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	3.72e-05	0.000986	CbGpPWpGaD
Carmustine—Anaemia—Methotrexate—urinary bladder cancer	3.71e-05	0.000396	CcSEcCtD
Carmustine—Flushing—Doxorubicin—urinary bladder cancer	3.71e-05	0.000395	CcSEcCtD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.7e-05	0.000982	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	3.64e-05	0.000964	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	3.64e-05	0.000964	CbGpPWpGaD
Carmustine—Back pain—Epirubicin—urinary bladder cancer	3.64e-05	0.000388	CcSEcCtD
Carmustine—Dizziness—Etoposide—urinary bladder cancer	3.62e-05	0.000386	CcSEcCtD
Carmustine—Leukopenia—Methotrexate—urinary bladder cancer	3.6e-05	0.000383	CcSEcCtD
Carmustine—Arrhythmia—Doxorubicin—urinary bladder cancer	3.57e-05	0.00038	CcSEcCtD
Carmustine—Nausea—Cisplatin—urinary bladder cancer	3.55e-05	0.000378	CcSEcCtD
Carmustine—Vision blurred—Epirubicin—urinary bladder cancer	3.54e-05	0.000378	CcSEcCtD
Carmustine—Alopecia—Doxorubicin—urinary bladder cancer	3.53e-05	0.000376	CcSEcCtD
Carmustine—Mental disorder—Doxorubicin—urinary bladder cancer	3.5e-05	0.000373	CcSEcCtD
Carmustine—Convulsion—Methotrexate—urinary bladder cancer	3.48e-05	0.000371	CcSEcCtD
Carmustine—Vomiting—Etoposide—urinary bladder cancer	3.48e-05	0.000371	CcSEcCtD
Carmustine—Malnutrition—Doxorubicin—urinary bladder cancer	3.48e-05	0.000371	CcSEcCtD
Carmustine—Erythema—Doxorubicin—urinary bladder cancer	3.48e-05	0.000371	CcSEcCtD
Carmustine—Anaemia—Epirubicin—urinary bladder cancer	3.47e-05	0.00037	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	3.47e-05	0.000918	CbGpPWpGaD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	3.47e-05	0.000918	CbGpPWpGaD
Carmustine—Agitation—Epirubicin—urinary bladder cancer	3.45e-05	0.000368	CcSEcCtD
Carmustine—Rash—Etoposide—urinary bladder cancer	3.45e-05	0.000368	CcSEcCtD
Carmustine—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	3.45e-05	0.000914	CbGpPWpGaD
Carmustine—Dermatitis—Etoposide—urinary bladder cancer	3.45e-05	0.000367	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	3.44e-05	0.000911	CbGpPWpGaD
Carmustine—Headache—Etoposide—urinary bladder cancer	3.43e-05	0.000365	CcSEcCtD
Carmustine—Myalgia—Methotrexate—urinary bladder cancer	3.42e-05	0.000365	CcSEcCtD
Carmustine—Chest pain—Methotrexate—urinary bladder cancer	3.42e-05	0.000365	CcSEcCtD
Carmustine—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.4e-05	0.000902	CbGpPWpGaD
Carmustine—Leukopenia—Epirubicin—urinary bladder cancer	3.36e-05	0.000359	CcSEcCtD
Carmustine—Back pain—Doxorubicin—urinary bladder cancer	3.36e-05	0.000359	CcSEcCtD
Carmustine—Confusional state—Methotrexate—urinary bladder cancer	3.31e-05	0.000352	CcSEcCtD
Carmustine—Vision blurred—Doxorubicin—urinary bladder cancer	3.28e-05	0.000349	CcSEcCtD
Carmustine—Convulsion—Epirubicin—urinary bladder cancer	3.26e-05	0.000347	CcSEcCtD
Carmustine—Infection—Methotrexate—urinary bladder cancer	3.26e-05	0.000347	CcSEcCtD
Carmustine—Nausea—Etoposide—urinary bladder cancer	3.25e-05	0.000347	CcSEcCtD
Carmustine—Hypertension—Epirubicin—urinary bladder cancer	3.25e-05	0.000346	CcSEcCtD
Carmustine—Anaemia—Doxorubicin—urinary bladder cancer	3.21e-05	0.000343	CcSEcCtD
Carmustine—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.21e-05	0.000342	CcSEcCtD
Carmustine—Chest pain—Epirubicin—urinary bladder cancer	3.2e-05	0.000341	CcSEcCtD
Carmustine—Myalgia—Epirubicin—urinary bladder cancer	3.2e-05	0.000341	CcSEcCtD
Carmustine—Agitation—Doxorubicin—urinary bladder cancer	3.2e-05	0.000341	CcSEcCtD
Carmustine—Anxiety—Epirubicin—urinary bladder cancer	3.19e-05	0.00034	CcSEcCtD
Carmustine—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	3.17e-05	0.00084	CbGpPWpGaD
Carmustine—GSR—Metabolism—PPARG—urinary bladder cancer	3.16e-05	0.000837	CbGpPWpGaD
Carmustine—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.13e-05	0.000829	CbGpPWpGaD
Carmustine—Anorexia—Methotrexate—urinary bladder cancer	3.12e-05	0.000333	CcSEcCtD
Carmustine—Leukopenia—Doxorubicin—urinary bladder cancer	3.11e-05	0.000332	CcSEcCtD
Carmustine—Confusional state—Epirubicin—urinary bladder cancer	3.09e-05	0.00033	CcSEcCtD
Carmustine—Oedema—Epirubicin—urinary bladder cancer	3.07e-05	0.000327	CcSEcCtD
Carmustine—Hypotension—Methotrexate—urinary bladder cancer	3.06e-05	0.000327	CcSEcCtD
Carmustine—Infection—Epirubicin—urinary bladder cancer	3.05e-05	0.000325	CcSEcCtD
Carmustine—GSR—Metabolism—CREBBP—urinary bladder cancer	3.03e-05	0.000804	CbGpPWpGaD
Carmustine—Convulsion—Doxorubicin—urinary bladder cancer	3.01e-05	0.000321	CcSEcCtD
Carmustine—Thrombocytopenia—Epirubicin—urinary bladder cancer	3e-05	0.00032	CcSEcCtD
Carmustine—Hypertension—Doxorubicin—urinary bladder cancer	3e-05	0.00032	CcSEcCtD
Carmustine—Tachycardia—Epirubicin—urinary bladder cancer	2.99e-05	0.000319	CcSEcCtD
Carmustine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.99e-05	0.000318	CcSEcCtD
Carmustine—Insomnia—Methotrexate—urinary bladder cancer	2.97e-05	0.000316	CcSEcCtD
Carmustine—Chest pain—Doxorubicin—urinary bladder cancer	2.96e-05	0.000316	CcSEcCtD
Carmustine—Myalgia—Doxorubicin—urinary bladder cancer	2.96e-05	0.000316	CcSEcCtD
Carmustine—Anxiety—Doxorubicin—urinary bladder cancer	2.95e-05	0.000315	CcSEcCtD
Carmustine—Paraesthesia—Methotrexate—urinary bladder cancer	2.94e-05	0.000314	CcSEcCtD
Carmustine—Anorexia—Epirubicin—urinary bladder cancer	2.92e-05	0.000312	CcSEcCtD
Carmustine—Dyspnoea—Methotrexate—urinary bladder cancer	2.92e-05	0.000312	CcSEcCtD
Carmustine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	2.92e-05	0.000774	CbGpPWpGaD
Carmustine—Somnolence—Methotrexate—urinary bladder cancer	2.91e-05	0.000311	CcSEcCtD
Carmustine—Hypotension—Epirubicin—urinary bladder cancer	2.87e-05	0.000306	CcSEcCtD
Carmustine—Confusional state—Doxorubicin—urinary bladder cancer	2.86e-05	0.000305	CcSEcCtD
Carmustine—Decreased appetite—Methotrexate—urinary bladder cancer	2.85e-05	0.000304	CcSEcCtD
Carmustine—Oedema—Doxorubicin—urinary bladder cancer	2.84e-05	0.000303	CcSEcCtD
Carmustine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.83e-05	0.000302	CcSEcCtD
Carmustine—Infection—Doxorubicin—urinary bladder cancer	2.82e-05	0.000301	CcSEcCtD
Carmustine—Pain—Methotrexate—urinary bladder cancer	2.8e-05	0.000299	CcSEcCtD
Carmustine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.8e-05	0.000298	CcSEcCtD
Carmustine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.78e-05	0.000296	CcSEcCtD
Carmustine—Insomnia—Epirubicin—urinary bladder cancer	2.77e-05	0.000296	CcSEcCtD
Carmustine—Tachycardia—Doxorubicin—urinary bladder cancer	2.77e-05	0.000295	CcSEcCtD
Carmustine—Paraesthesia—Epirubicin—urinary bladder cancer	2.75e-05	0.000294	CcSEcCtD
Carmustine—Dyspnoea—Epirubicin—urinary bladder cancer	2.74e-05	0.000292	CcSEcCtD
Carmustine—Somnolence—Epirubicin—urinary bladder cancer	2.73e-05	0.000291	CcSEcCtD
Carmustine—Anorexia—Doxorubicin—urinary bladder cancer	2.71e-05	0.000288	CcSEcCtD
Carmustine—Feeling abnormal—Methotrexate—urinary bladder cancer	2.7e-05	0.000288	CcSEcCtD
Carmustine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.68e-05	0.000286	CcSEcCtD
Carmustine—Decreased appetite—Epirubicin—urinary bladder cancer	2.67e-05	0.000284	CcSEcCtD
Carmustine—Hypotension—Doxorubicin—urinary bladder cancer	2.65e-05	0.000283	CcSEcCtD
Carmustine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.65e-05	0.000282	CcSEcCtD
Carmustine—Constipation—Epirubicin—urinary bladder cancer	2.62e-05	0.00028	CcSEcCtD
Carmustine—Pain—Epirubicin—urinary bladder cancer	2.62e-05	0.00028	CcSEcCtD
Carmustine—Body temperature increased—Methotrexate—urinary bladder cancer	2.59e-05	0.000276	CcSEcCtD
Carmustine—Abdominal pain—Methotrexate—urinary bladder cancer	2.59e-05	0.000276	CcSEcCtD
Carmustine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.59e-05	0.000276	CcSEcCtD
Carmustine—Insomnia—Doxorubicin—urinary bladder cancer	2.57e-05	0.000274	CcSEcCtD
Carmustine—Paraesthesia—Doxorubicin—urinary bladder cancer	2.55e-05	0.000272	CcSEcCtD
Carmustine—Dyspnoea—Doxorubicin—urinary bladder cancer	2.53e-05	0.00027	CcSEcCtD
Carmustine—Feeling abnormal—Epirubicin—urinary bladder cancer	2.53e-05	0.000269	CcSEcCtD
Carmustine—Somnolence—Doxorubicin—urinary bladder cancer	2.52e-05	0.000269	CcSEcCtD
Carmustine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.51e-05	0.000267	CcSEcCtD
Carmustine—GSR—Metabolism—PTGS2—urinary bladder cancer	2.48e-05	0.000658	CbGpPWpGaD
Carmustine—Decreased appetite—Doxorubicin—urinary bladder cancer	2.47e-05	0.000263	CcSEcCtD
Carmustine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.45e-05	0.000261	CcSEcCtD
Carmustine—Pain—Doxorubicin—urinary bladder cancer	2.43e-05	0.000259	CcSEcCtD
Carmustine—Constipation—Doxorubicin—urinary bladder cancer	2.43e-05	0.000259	CcSEcCtD
Carmustine—Abdominal pain—Epirubicin—urinary bladder cancer	2.43e-05	0.000259	CcSEcCtD
Carmustine—Body temperature increased—Epirubicin—urinary bladder cancer	2.43e-05	0.000259	CcSEcCtD
Carmustine—Hypersensitivity—Methotrexate—urinary bladder cancer	2.42e-05	0.000257	CcSEcCtD
Carmustine—Asthenia—Methotrexate—urinary bladder cancer	2.35e-05	0.000251	CcSEcCtD
Carmustine—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.34e-05	0.000249	CcSEcCtD
Carmustine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.32e-05	0.000247	CcSEcCtD
Carmustine—Hypersensitivity—Epirubicin—urinary bladder cancer	2.26e-05	0.000241	CcSEcCtD
Carmustine—Body temperature increased—Doxorubicin—urinary bladder cancer	2.24e-05	0.000239	CcSEcCtD
Carmustine—Abdominal pain—Doxorubicin—urinary bladder cancer	2.24e-05	0.000239	CcSEcCtD
Carmustine—Diarrhoea—Methotrexate—urinary bladder cancer	2.24e-05	0.000239	CcSEcCtD
Carmustine—Asthenia—Epirubicin—urinary bladder cancer	2.2e-05	0.000235	CcSEcCtD
Carmustine—Dizziness—Methotrexate—urinary bladder cancer	2.17e-05	0.000231	CcSEcCtD
Carmustine—GSR—Metabolism—PTEN—urinary bladder cancer	2.17e-05	0.000574	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	2.11e-05	0.00056	CbGpPWpGaD
Carmustine—Diarrhoea—Epirubicin—urinary bladder cancer	2.1e-05	0.000224	CcSEcCtD
Carmustine—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.09e-05	0.000223	CcSEcCtD
Carmustine—Vomiting—Methotrexate—urinary bladder cancer	2.08e-05	0.000222	CcSEcCtD
Carmustine—Rash—Methotrexate—urinary bladder cancer	2.07e-05	0.00022	CcSEcCtD
Carmustine—GSR—Metabolism—EP300—urinary bladder cancer	2.07e-05	0.000547	CbGpPWpGaD
Carmustine—Dermatitis—Methotrexate—urinary bladder cancer	2.07e-05	0.00022	CcSEcCtD
Carmustine—Headache—Methotrexate—urinary bladder cancer	2.05e-05	0.000219	CcSEcCtD
Carmustine—Asthenia—Doxorubicin—urinary bladder cancer	2.04e-05	0.000217	CcSEcCtD
Carmustine—Dizziness—Epirubicin—urinary bladder cancer	2.03e-05	0.000216	CcSEcCtD
Carmustine—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	2e-05	0.000531	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—NAT1—urinary bladder cancer	2e-05	0.000531	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.97e-05	0.000522	CbGpPWpGaD
Carmustine—Vomiting—Epirubicin—urinary bladder cancer	1.95e-05	0.000208	CcSEcCtD
Carmustine—Nausea—Methotrexate—urinary bladder cancer	1.95e-05	0.000208	CcSEcCtD
Carmustine—Diarrhoea—Doxorubicin—urinary bladder cancer	1.94e-05	0.000207	CcSEcCtD
Carmustine—Rash—Epirubicin—urinary bladder cancer	1.93e-05	0.000206	CcSEcCtD
Carmustine—Dermatitis—Epirubicin—urinary bladder cancer	1.93e-05	0.000206	CcSEcCtD
Carmustine—Headache—Epirubicin—urinary bladder cancer	1.92e-05	0.000205	CcSEcCtD
Carmustine—Dizziness—Doxorubicin—urinary bladder cancer	1.88e-05	0.0002	CcSEcCtD
Carmustine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	1.83e-05	0.000486	CbGpPWpGaD
Carmustine—Nausea—Epirubicin—urinary bladder cancer	1.82e-05	0.000194	CcSEcCtD
Carmustine—Vomiting—Doxorubicin—urinary bladder cancer	1.8e-05	0.000192	CcSEcCtD
Carmustine—Rash—Doxorubicin—urinary bladder cancer	1.79e-05	0.000191	CcSEcCtD
Carmustine—Dermatitis—Doxorubicin—urinary bladder cancer	1.79e-05	0.000191	CcSEcCtD
Carmustine—Headache—Doxorubicin—urinary bladder cancer	1.78e-05	0.00019	CcSEcCtD
Carmustine—Nausea—Doxorubicin—urinary bladder cancer	1.69e-05	0.00018	CcSEcCtD
Carmustine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.65e-05	0.000437	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	1.56e-05	0.000413	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.52e-05	0.000402	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.22e-05	0.000323	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.21e-05	0.000322	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.17e-05	0.000309	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.1e-05	0.000291	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	9.47e-06	0.000251	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	8.77e-06	0.000233	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	8.77e-06	0.000233	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.72e-06	0.000231	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	8.51e-06	0.000226	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.38e-06	0.000222	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	7.07e-06	0.000187	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.86e-06	0.000182	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.98e-06	0.000159	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	5.9e-06	0.000156	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.71e-06	0.000151	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	5.48e-06	0.000145	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	5.42e-06	0.000144	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	5.42e-06	0.000144	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	5.19e-06	0.000138	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	5.1e-06	0.000135	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	4.79e-06	0.000127	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	3.88e-06	0.000103	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	3.73e-06	9.89e-05	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.06e-06	8.1e-05	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	2.67e-06	7.06e-05	CbGpPWpGaD
Carmustine—CYP1A2—Metabolism—EP300—urinary bladder cancer	2.54e-06	6.74e-05	CbGpPWpGaD
